Multiple Sclerosis (MS): Disease Mechanisms, Treatment Landscape, and the Role of Regenerative Medicine

What Is Multiple Sclerosis?

Multiple sclerosis (MS) is a chronic autoimmune condition that targets the central nervous system (CNS). In MS, the body’s immune cells mistakenly identify myelin, the fatty insulation wrapped around nerve fibers, as a foreign invader and begin destroying it. This process, called demyelination, disrupts the electrical signals traveling between the brain, spinal cord, and the rest of the body.

Think of myelin like the rubber coating on an electrical wire. When that coating gets damaged, the signal slows down, short-circuits, or stops entirely. That is exactly what happens in MS. Over time, the nerve fibers themselves can also become damaged, a process called axonal degeneration, which contributes to the progressive disability seen in later stages of the disease.

The exact cause of MS remains unknown, but researchers believe it results from a combination of genetic susceptibility, environmental triggers (such as low vitamin D, Epstein-Barr virus infection, and smoking), and immune system dysregulation. It is not a single-gene disease. Rather, over 200 genetic variants have been linked to increased MS risk, most of them related to immune function.

Types of Multiple Sclerosis

MS is not one disease. It is a spectrum with four recognized clinical courses:

Symptoms of Multiple Sclerosis

MS symptoms vary widely depending on which nerve fibers are affected. No two patients experience the disease in exactly the same way. That said, some symptoms show up far more often than others:

• Fatigue: The most common symptom, reported by up to 80% of patients. This is not ordinary tiredness. MS fatigue is a crushing, disproportionate exhaustion that can make simple tasks feel impossible.
• Numbness and tingling: Often one of the earliest symptoms, typically affecting the face, arms, legs, or trunk.
• Vision problems: Optic neuritis (inflammation of the optic nerve) causes pain with eye movement and temporary vision loss. It is frequently the first sign of MS.
• Muscle weakness and spasticity: Stiffness, involuntary muscle spasms, and weakness, particularly in the legs.
• Balance and coordination issues: Difficulty walking, dizziness, and tremors related to cerebellar involvement.
• Cognitive changes: Problems with memory, attention, information processing speed, and executive function affect roughly 50% of patients.
• Bladder and bowel dysfunction: Urgency, frequency, and incontinence are common as the disease progresses.
• Pain: Neuropathic pain, trigeminal neuralgia, and musculoskeletal pain affect up to 75% of patients at some point.
• Depression and emotional changes: Depression is 2 to 3 times more common in MS than in the general population.

How MS Is Diagnosed

There is no single test for MS. Diagnosis relies on the revised McDonald criteria (updated in 2017), which require evidence of damage disseminated in both time and space, meaning lesions in at least two different areas of the CNS that occurred at different times. Doctors use a combination of:

1. MRI of the brain and spinal cord: The gold standard. MRI can detect demyelinating lesions (plaques) and gadolinium-enhancing lesions that indicate active inflammation.
2. Lumbar puncture (spinal tap): Cerebrospinal fluid is analyzed for oligoclonal bands, which are immunoglobulin patterns found in 85 to 95% of confirmed MS cases.
3. Evoked potentials: These tests measure the speed of electrical signals along nerve pathways and can reveal demyelination even when MRI is inconclusive.
4. Blood tests: Used primarily to rule out conditions that mimic MS, such as neuromyelitis optica spectrum disorder (NMOSD), lupus, sarcoidosis, and vitamin B12 deficiency.

Conventional Disease-Modifying Therapies (DMTs)

Over the past three decades, the treatment of MS has changed dramatically. There are now more than 20 FDA-approved disease-modifying therapies. These drugs do not cure MS, but they reduce relapse rates, slow the accumulation of new lesions, and in some cases delay disability progression.

DMTs generally fall into several categories based on their mechanism and potency:

• Injectable platform therapies: Interferon beta preparations (Avonex, Rebif, Betaseron) and glatiramer acetate (Copaxone). These were the first DMTs approved and remain widely used for mild to moderate RRMS.
• Oral therapies: Fingolimod (Gilenya), dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), siponimod (Mayzent), ozanimod (Zeposia), cladribine (Mavenclad). These offer convenience and varying levels of efficacy.
• Infusion therapies: Natalizumab (Tysabri), ocrelizumab (Ocrevus), ofatumumab (Kesimpta), alemtuzumab (Lemtrada). These are typically reserved for more active or aggressive disease and tend to be the most potent options.
• B-cell depleting therapies: Ocrelizumab and ofatumumab target CD20-positive B cells and have become particularly important because ocrelizumab is the only FDA-approved treatment for PPMS.

The choice of DMT depends on disease activity, patient preferences, risk tolerance, and the presence of comorbidities. Many neurologists now favor a “treat early, treat effectively” approach, sometimes starting with high-efficacy therapies rather than escalating from milder options.

Regenerative and Integrative Approaches to MS

While conventional DMTs focus on suppressing the immune attack, regenerative medicine takes a different angle: supporting the body’s ability to repair damaged myelin, reduce neuroinflammation through non-immunosuppressive pathways, and protect surviving neurons. These approaches are not replacements for standard care. They are potential additions to a treatment plan, especially for patients who have plateaued on conventional therapy or who are dealing with progressive disease where fewer options exist.

Hyperbaric Oxygen Therapy (HBOT)

Hyperbaric oxygen therapy involves breathing 100% oxygen at pressures greater than atmospheric in a sealed chamber. In the context of MS, HBOT is proposed to reduce neuroinflammation, improve oxygen delivery to damaged CNS tissue, and support remyelination processes.

The rationale is straightforward: demyelinated neurons are more metabolically vulnerable. They require more energy to conduct signals, and when local oxygen supply is insufficient, they degenerate faster. HBOT may help by flooding tissues with dissolved oxygen, reducing edema, and modulating inflammatory cytokines.

Clinical evidence is mixed but promising in select areas. Some studies report improvements in fatigue, bladder function, and quality of life scores, while effects on disability progression have been harder to confirm in controlled trials. HBOT is generally well tolerated, with the most common side effect being mild barotrauma to the ears.

Stem Cell Therapy

Stem cell therapy represents one of the most actively researched regenerative strategies for MS. Two main approaches are being studied:

• Autologous hematopoietic stem cell transplantation (aHSCT): This involves harvesting a patient’s own stem cells, using chemotherapy to ablate the immune system, then reinfusing the stem cells to “reboot” the immune system. The MIST trial and the BEAT-MS trial have shown that aHSCT can be superior to conventional DMTs for highly active RRMS, with some patients achieving long-term remission without ongoing medication.
• Mesenchymal stem cells (MSCs): These cells, often derived from bone marrow, adipose tissue, or umbilical cord, are being studied for their immunomodulatory and neuroprotective properties. Unlike aHSCT, MSC therapy does not require immune ablation and carries less procedural risk. The MESEMS trial (a multicenter phase II study) evaluated MSC infusions in MS and found a favorable safety profile.

Low-Dose Naltrexone (LDN)

Low-dose naltrexone uses naltrexone at doses of 1.5 to 4.5 mg (far below the 50 mg dose used for addiction treatment) to modulate the immune system. LDN is thought to briefly block opioid receptors, triggering a compensatory increase in endorphin and enkephalin production. These endogenous opioids then act on opioid growth factor receptors on immune cells, promoting a shift from pro-inflammatory to regulatory immune activity.

For MS patients, LDN has been studied primarily for fatigue and quality of life. A 2010 pilot study published in Annals of Neurology found that LDN improved mental health quality of life scores compared to placebo. Patient-reported experiences are often enthusiastic, though large-scale randomized controlled trials are still needed. LDN is inexpensive, has a favorable side-effect profile, and is typically obtained through compounding pharmacies.

Peptide Therapy

Peptide therapy uses short chains of amino acids to target specific biological pathways. Several peptides are being explored in the context of neuroinflammation and neuroprotection:

• BPC-157: A gastric pentadecapeptide with anti-inflammatory and tissue-healing properties. Preclinical data suggests it may support nerve repair and reduce inflammation in CNS injury models.
• Thymosin alpha-1: An immune-modulating peptide that enhances regulatory T-cell function. It may help rebalance the immune system in autoimmune conditions without broadly suppressing immunity.
• KPV: A tripeptide derived from alpha-melanocyte-stimulating hormone with potent anti-inflammatory effects. It has shown promise in reducing inflammatory cytokine production in preclinical studies.

Peptide therapy for MS is still in early stages, and most evidence comes from animal models or small clinical series. However, the specificity and low toxicity of peptides make them an area of active investigation.

NAD+ Infusion Therapy

NAD+ (nicotinamide adenine dinucleotide) infusion therapy delivers this essential coenzyme directly into the bloodstream. NAD+ plays a central role in cellular energy production, DNA repair, and the activity of sirtuins, a family of proteins involved in inflammation regulation and neuroprotection.

In MS, mitochondrial dysfunction is increasingly recognized as a driver of neurodegeneration, particularly in progressive forms of the disease. Demyelinated axons require significantly more energy to maintain signal conduction, and when mitochondria cannot keep up, the axon degenerates. NAD+ supplementation aims to support mitochondrial function and reduce the energy deficit that contributes to progressive disability.

Research on NAD+ in MS specifically is still emerging. However, studies in other neurodegenerative conditions have shown that boosting NAD+ levels can improve mitochondrial function, reduce oxidative stress, and activate neuroprotective pathways. A 2022 study in Cell Metabolism demonstrated that NAD+ precursors could reduce neuroinflammation in animal models of CNS autoimmunity.

Evidence Summary: Regenerative Approaches for MS

The following table summarizes the current level of evidence for each regenerative therapy discussed above. Evidence levels range from preclinical (animal and in vitro studies only) to strong clinical evidence (multiple randomized controlled trials).

Diet, Lifestyle, and the Gut-Brain Connection

What you eat and how you live can meaningfully influence MS disease activity. While no diet has been proven to cure MS, several dietary strategies have shown promise in reducing inflammation, improving energy, and supporting neurological function.

The Wahls Protocol

Developed by Dr. Terry Wahls, a physician with secondary progressive MS who used dietary changes as part of her own recovery, the Wahls Protocol emphasizes nutrient-dense, anti-inflammatory eating. The protocol calls for 9 cups of fruits and vegetables daily (3 cups of leafy greens, 3 cups of sulfur-rich vegetables, 3 cups of deeply colored fruits and vegetables), along with grass-fed meats, organ meats, wild-caught fish, and fermented foods. It eliminates gluten, dairy, and processed foods.

A 2022 randomized controlled trial published in Annals of Neurology compared the Wahls diet to the Swank diet (a low-saturated-fat approach) in 95 people with relapsing MS. Both groups showed reduced fatigue, but the Wahls group demonstrated significant improvements in quality of life and walking speed.

Vitamin D

The connection between vitamin D and MS is one of the most consistent findings in the field. MS prevalence increases with distance from the equator, and low vitamin D levels are associated with higher relapse rates and more active disease on MRI. Several studies suggest that maintaining serum 25-hydroxyvitamin D levels above 40 ng/mL (and potentially above 60 ng/mL) may help reduce disease activity.

Vitamin D is not just a vitamin. It functions as a hormone that modulates over 200 genes involved in immune regulation. For MS patients, optimizing vitamin D status is one of the most accessible and well-supported interventions available. Most MS specialists now routinely monitor and supplement vitamin D.

The Gut-Brain Axis and SIBO

The gut-brain axis, the bidirectional communication network between the gastrointestinal tract and the central nervous system, is increasingly recognized as relevant to MS. Research has shown that MS patients have distinct gut microbiome profiles compared to healthy controls, with reduced microbial diversity and altered ratios of specific bacterial species.

Gut dysbiosis can contribute to a “leaky gut,” allowing bacterial products like lipopolysaccharide (LPS) to enter the bloodstream and trigger systemic inflammation that may worsen neuroinflammation. Small intestinal bacterial overgrowth (SIBO), a condition where bacteria proliferate abnormally in the small intestine, is more common in autoimmune populations and can further disrupt immune balance.

Addressing gut health through dietary changes, probiotics (particularly strains like Lactobacillus and Bifidobacterium), and treating conditions like SIBO may be an underappreciated piece of the MS management puzzle.

Other Lifestyle Factors

• Exercise: Regular physical activity improves fatigue, mood, mobility, and cardiovascular health in MS patients. Both aerobic exercise and resistance training are supported by evidence. The old advice to avoid exercise in MS has been completely reversed.
• Sleep: Sleep disorders are common in MS and significantly worsen fatigue and cognition. Screening for and treating sleep apnea, restless leg syndrome, and insomnia should be part of standard MS care.
• Stress management: Chronic stress is associated with increased relapse risk. Mindfulness-based stress reduction (MBSR) has been studied in MS and shown to improve quality of life and reduce anxiety and depression.
• Smoking cessation: Smoking accelerates MS progression and reduces the effectiveness of DMTs. Quitting is one of the single most impactful lifestyle changes an MS patient can make.

Frequently Asked Questions

Is MS a fatal disease?

MS itself is rarely directly fatal. Most people with MS have a life expectancy that is 5 to 10 years shorter than average, and this gap has been narrowing with modern treatments. The primary causes of reduced life expectancy are complications related to severe disability (such as infections from immobility) and comorbidities. With early treatment and good management, many patients live full, active lives.

Can MS go into remission permanently?

Some patients experience long periods of stability where the disease appears inactive, particularly with effective DMT use. In rare cases after aHSCT, patients have achieved what appears to be sustained remission for 10 or more years without ongoing medication. However, “cure” is not a word neurologists use for MS at this point. Long-term remission is the realistic goal, and it is achievable for a growing number of patients.

Are regenerative therapies safe to use alongside conventional DMTs?

This depends entirely on the specific therapies involved. Some combinations are straightforward. For example, HBOT, vitamin D optimization, and dietary changes are generally compatible with any DMT. Others require more caution. LDN may interact with opioid-based pain medications, and stem cell transplantation requires temporary discontinuation of immunosuppressive DMTs. Always discuss any additions to your treatment plan with your neurologist.

How do I know which type of MS I have?

Your neurologist determines your MS type based on your clinical history and disease course over time. If you have had distinct relapses with recovery periods, you likely have RRMS. If your function has been gradually declining from the start without clear relapses, you may have PPMS. SPMS is diagnosed when an RRMS patient begins to show steady progression independent of relapses. MRI patterns and clinical assessments help confirm the classification.

What is the role of the gut microbiome in MS?

Research increasingly shows that the gut microbiome plays a significant role in immune regulation and may influence MS disease activity. MS patients tend to have less microbial diversity and different bacterial compositions than healthy controls. Some studies have found that specific gut bacteria can either promote or suppress neuroinflammation in animal models. While we cannot yet prescribe a specific probiotic “cocktail” to treat MS, optimizing gut health through diet, treating dysbiosis, and addressing conditions like SIBO is a reasonable and low-risk strategy.

Is vitamin D supplementation enough to manage MS?

No. Vitamin D is an important adjunct, not a standalone treatment. While evidence strongly supports maintaining optimal vitamin D levels (typically 40 to 80 ng/mL), it should not replace disease-modifying therapy. Think of vitamin D as one piece of a larger puzzle that includes DMTs, lifestyle modifications, and potentially regenerative therapies.

What should I do if I suspect I have MS?

See a neurologist, ideally one who specializes in MS or neuroimmunology. Early diagnosis and treatment are critical. If you are experiencing symptoms like unexplained numbness, vision changes, or unusual fatigue, do not wait. Request an MRI of the brain and spinal cord with and without gadolinium contrast. The sooner demyelinating disease is identified, the sooner treatment can begin to preserve neurological function.

Related Guides

• Hyperbaric Oxygen Therapy (HBOT): How It Works and What It Treats
• Stem Cell Therapy: Types, Applications, and What to Expect
• Low-Dose Naltrexone (LDN): Mechanism, Uses, and Evidence
• Peptide Therapy: A Guide to Therapeutic Peptides
• NAD+ IV Therapy: Cellular Energy and Neuroprotection
• SIBO: Causes, Testing, and Treatment Options

References

1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
2. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821.
3. Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial (MIST). JAMA. 2019;321(2):165-174.
4. Uccelli A, Laroni A, Brundin L, et al. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019;20(1):263.
5. Cree BA, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363.
6. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008;14(8):1076-1083.
7. Wahls TL, Chenard CA, Grinbank D, et al. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis. Nutrients. 2019;11(2):352.
8. Fitzgerald KC, Munger KL, Kochert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol. 2015;72(12):1458-1465.
9. Bennett M, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev. 2004;(1):CD003057.
10. Colafrancesco S, Agmon-Levin N, Engel P, et al. The gut-brain axis in multiple sclerosis: Is its dysfunction a pathological trigger or a consequence of the disease? Front Immunol. 2020;11:1741.
11. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647-656.
12. Schoenfeld R, Wong A, Silva J, et al. Oligodendroglial differentiation induces mitochondrial genes and inhibition of mitochondrial function represses oligodendroglial differentiation. Mitochondrion. 2010;10(2):143-150.
13. Cantoni C, Lin Q, Dorsett Y, et al. Alterations of host-gut microbiome interactions in multiple sclerosis. EBioMedicine. 2022;76:103798.
14. Motl RW, Sandroff BM, Kwakkel G, et al. Exercise in patients with multiple sclerosis. Lancet Neurol. 2017;16(10):848-856.